BioDrugs

, Volume 15, Issue 8, pp 543–561 | Cite as

Combination Therapy with Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis

Review Article

Abstract

There is increasing interest in using combinations of two or more disease modifying anti-rheumatic drugs to treat rheumatoid arthritis. The use of such combinations is increasing in routine clinical practice. We have identified 18 well-conducted, randomised controlled trials of the use of combinations of disease modifying drugs, and a number of open studies that provide helpful supportive information. The 18 trials involved 2221 patients. Two trials reported strongly positive results, six reported moderately positive results and ten gave largely negative results. The combination of methotrexate, sulfasalazine and hydroxy-chloroquine appears to be effective with an acceptable level of adverse effects. There is also evidence that the combination of methotrexate and cyclosporin is advantageous. With both combinations, there appears to be further advantages from using corticosteroids in addition to the combination, although the evidence for this is incomplete. The use of other combinations is of less value, and in particular combinations involving parenteral gold, penicillamine and azathioprine are best avoided. Finally, there is growing evidence from randomised trials that the combination of anti-tumour necrosis factor (TNF) therapy with methotrexate is effective and well tolerated. We have identified four randomised controlled trials of the use of combinations of anti-TNF with methotrexate that all reported results favouring this combination. There is insufficient evidence to support the use of other combinations involving immunotherapies at the present time.

References

  1. 1.
    van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with ’second-line’ antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996; 124: 699–707PubMedGoogle Scholar
  2. 2.
    Emery P. Rheumatoid arthritis: not yet curable with early intensive therapy. Lancet 1997; 350: 304–5PubMedCrossRefGoogle Scholar
  3. 3.
    Brook A, Corbett M. Radiographic changes in early rheumatoid disease. Ann Rheum Dis 1977; 36: 71–3PubMedCrossRefGoogle Scholar
  4. 4.
    Wolfe F, Hawley DJ, Cathey MA. Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis. J Rheumatol 1991; 18: 1290–7PubMedGoogle Scholar
  5. 5.
    Munro R, Hampson R, McEntegart A, et al. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann Rheum Dis 1998; 57: 88–93PubMedCrossRefGoogle Scholar
  6. 6.
    Van Jaarsveld CH, Jacobs JW, van der Veen MJ, et al. Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis 2000; 59: 468–77PubMedCrossRefGoogle Scholar
  7. 7.
    Bensen WG, Bensen W, Adachi JD. Back to the future: the pyramids of rheumatoid arthritis. J Rheumatol 1997; 24: 1023–7PubMedGoogle Scholar
  8. 8.
    Felson DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis. Arthritis Rheum 1994; 37: 1487–91CrossRefGoogle Scholar
  9. 9.
    Pincus T. Limitations of randomized clinical trials to recognize possible advantages of combination therapies in rheumatic diseases. Semin Arthritis Rheum 1993; 23: 2–10PubMedCrossRefGoogle Scholar
  10. 10.
    Hawley DJ, Wolfe F, Pincus T. Use of combination therapy in the routine care of patients with rheumatoid arthritis: physician and patient surveys. Clin Exp Rheumatol 1999; 17: S78–82PubMedGoogle Scholar
  11. 11.
    Mikuls TR, O’Dell J. The changing face of rheumatoid arthritis therapy: results of serial surveys. Arthritis Rheum 2000; 43: 464–5PubMedCrossRefGoogle Scholar
  12. 12.
    Zink A, Listing J, Niewerth M, et al. The national database of the German Collaborative Arthritis Centres: II.Treatment of patients with rheumatoid arthritis. Ann Rheum Dis 2001; 60: 207–13PubMedCrossRefGoogle Scholar
  13. 13.
    Andersen PA, West SG, O’Dell JR, et al. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985; 103: 489–96PubMedGoogle Scholar
  14. 14.
    Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818–22PubMedCrossRefGoogle Scholar
  15. 15.
    Drosos AA, Tsifetaki N, Tsiakou EK, et al. Influence of methotrexate on radiographic progression in rheumatoid arthritis: a sixty-month prospective study. Clin Exp Rheumatol 1997; 15: 263–7PubMedGoogle Scholar
  16. 16.
    Shiroky JB, Watts CS, Neville C. Combination methotrexate and sulfasalazine in the management of rheumatoid arthritis: case observations. Arthritis Rheum 1989; 32: 1160–4PubMedCrossRefGoogle Scholar
  17. 17.
    Nisar M, Carlisle L, Amos RS. Methotrexate and sulphasalazine as combination therapy in rheumatoid arthritis. Br J Rheumatol 1994; 33: 651–4PubMedCrossRefGoogle Scholar
  18. 18.
    O’Dell J, Haire C, Drymalski W, et al. Methotrexate-sulphasalazine-hydroxychloroquine combination therapy in rheumatoid arthritis: continued efficacy with minimal toxicity at 3 years. Arthritis Rheum 1996; 36: S123Google Scholar
  19. 19.
    Bensen W, Tugwell P, Roberts RM, et al. Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies). J Rheumatol 1994; 21: 2034–8PubMedGoogle Scholar
  20. 20.
    Salaffi F, Carotti M, Cervini C. Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis. Scand J Rheumatol 1996; 25: 16–23PubMedCrossRefGoogle Scholar
  21. 21.
    Dawes PT, Sheeran TP, Fowler PD, et al. Improving the response to gold or D-penicillamine by addition of sulphasalazine. Apilot study in 25 patients with rheumatoid arthritis. Clin Exp Rheumatol 1987; 5: 151–3PubMedGoogle Scholar
  22. 22.
    Rau R, Schleusser B, Herborn G, et al. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy. J Rheumatol 1998; 25: 1485–92PubMedGoogle Scholar
  23. 23.
    McCarty DJ, Carrera GF. Intractable rheumatoid arthritis. Treatment with combined cyclophosphamide, azathioprine, and hydroxychloroquine. JAMA 1982; 248: 1718–23PubMedCrossRefGoogle Scholar
  24. 24.
    Csuka M, Carrera GF, McCarty DJ. Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. A follow-up study. JAMA 1986; 255: 2315–9PubMedCrossRefGoogle Scholar
  25. 25.
    Waterworth RF. The use of sulphasalazine and azathioprine in combination to treat rheumatoid arthritis. Br J Rheumatol 1989; 28: 456PubMedGoogle Scholar
  26. 26.
    McCarty DJ, Harman JG, Grassanovich JL, et al. Combination drug therapy of seropositive rheumatoid arthritis. J Rheumatol 1995; 22: 1636–45PubMedGoogle Scholar
  27. 27.
    Blanco R, Martinez-Taboada VM, Gonzalez-Gay MA, et al. Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. Arthritis Rheum 1996; 39: 1016–20PubMedCrossRefGoogle Scholar
  28. 28.
    Weinblatt ME, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1322–8PubMedCrossRefGoogle Scholar
  29. 29.
    Shiroky JB. Unsubstantiated ‘risk’ of antifolate toxicity with combination methotrexate and sulfasalazine therapy. Arthritis Rheum 1993; 36: 1757–8PubMedCrossRefGoogle Scholar
  30. 30.
    Axtens RS, Morand EF, Littlejohn GO. Combination therapy with methotrexate and sulphasalazine in rheumatoid arthritis — tolerance of therapy. Ann Rheum Dis 1994; 53: 703PubMedCrossRefGoogle Scholar
  31. 31.
    Haagsma CJ, van Riel PL, de Rooij DJ, et al. Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. Br J Rheumatol 1994; 33: 1049–55PubMedCrossRefGoogle Scholar
  32. 32.
    Haagsma CJ, van Riel PL, de Jong AJ, et al. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997; 36: 1082–8PubMedCrossRefGoogle Scholar
  33. 33.
    Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999; 58: 220–5PubMedCrossRefGoogle Scholar
  34. 34.
    O’Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 1287–91PubMedCrossRefGoogle Scholar
  35. 35.
    Faarvang KL, Egsmose C, Kryger P, et al. Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial. Ann Rheum Dis 1993; 52: 711–5PubMedCrossRefGoogle Scholar
  36. 36.
    Ferraz MB, Pinheiro GR, Helfenstein M, et al. Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial. Scand J Rheumatol 1994; 23: 231–6PubMedCrossRefGoogle Scholar
  37. 37.
    Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309–18PubMedCrossRefGoogle Scholar
  38. 38.
    Möttonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999; 353: 1568–73PubMedCrossRefGoogle Scholar
  39. 39.
    Bendix G, Bjelle A. Adding low-dose cyclosporin A to parenteral gold therapy in rheumatoid arthritis: a double-blind placebo-controlled study. Br J Rheumatol 1996; 35: 1142–9PubMedCrossRefGoogle Scholar
  40. 40.
    Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333: 137–41PubMedCrossRefGoogle Scholar
  41. 41.
    van den Borne BE, Landewe RB, Goei The HS, et al. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J Rheumatol 1998; 25: 1493–8PubMedGoogle Scholar
  42. 42.
    Proudman SM, Conaghan PG, Richardson C, et al. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000; 43: 1809–19PubMedCrossRefGoogle Scholar
  43. 43.
    Scott DL, Dawes PT, Tunn E, et al. Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective, randomized, placebo-controlled study. Br J Rheumatol 1989; 28: 128–33PubMedCrossRefGoogle Scholar
  44. 44.
    Williams HJ, Ward JR, Reading JC, et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1992; 35: 259–69Google Scholar
  45. 45.
    Porter DR, Capell HA, Hunter J. Combination therapy in rheumatoid arthritis — no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy. J Rheumatol 1993; 20: 645–9PubMedGoogle Scholar
  46. 46.
    Bunch TW, O’Duffy JD, Tompkins RB, et al. Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis. Arthritis Rheum 1984; 27: 267–76PubMedCrossRefGoogle Scholar
  47. 47.
    Gibson T, Emery P, Armstrong RD, et al. Combined D-penicillamine and chloroquine treatment of rheumatoid arthritis — a comparative study. Br J Rheumatol 1987; 26: 279–84PubMedCrossRefGoogle Scholar
  48. 48.
    Willkens RF, Sharp JT, Stablein D, et al. Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. Arthritis Rheum 1995; 38: 1799–806PubMedCrossRefGoogle Scholar
  49. 49.
    DT Felson, JJ Anderson, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35CrossRefGoogle Scholar
  50. 50.
    Paulus HE, Egger MJ, Ward JR, et al. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990; 33: 477–84PubMedCrossRefGoogle Scholar
  51. 51.
    O’Dell JR, Haire C, Erikson N, et al. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. J Rheumatol 1996; Suppl. 44: 72-4Google Scholar
  52. 52.
    Clegg DO, Dietz F, Duffy J, et al. Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine. J Rheumatol 1997; 24: 1896–902PubMedGoogle Scholar
  53. 53.
    Wells G, Tugwell P. Cyclosporin A in rheumatoid arthritis: overview of efficacy. Br J Rheumatol 1993;32Suppl.1:51–6Google Scholar
  54. 54.
    Stein CM, Pincus T, Yocum D, et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The Methotrexate-Cyclosporine Combination Study Group. Arthritis Rheum 1997; 40: 1843–51PubMedCrossRefGoogle Scholar
  55. 55.
    Tirri G, La Montagna G, Salaffi F, et al. Combination therapy with cyclosporin and hydroxychloroquine in early active severe rheumatoid arthritis. Arthritis Rheum 1997; 40: S97Google Scholar
  56. 56.
    Rojkovich B, Hodinka L, Balint G, et al. Cyclosporin and sulfasalazine combination in the treatment of early rheumatoid arthritis. Scand J Rheumatol 1999; 28: 216–21PubMedCrossRefGoogle Scholar
  57. 57.
    Johns K, Littlejohn G. Clinical experience with combination disease-modifying antirheumatic drug therapy with cyclosporine. Clin Exp Rheumatol 1999; 17: S91–4PubMedGoogle Scholar
  58. 58.
    Sigler JW, Bluhm GB, Duncan H, et al. Gold salts in the treatment of rheumatoid arthritis. A double-blind study. Ann Intern Med 1974; 80: 21–6PubMedGoogle Scholar
  59. 59.
    Luukkainen R, Isomaki H, Kajander A. Effect of gold treatment on the progression of erosions in RA patients. Scand J Rheumatol 1977; 6: 123–7PubMedCrossRefGoogle Scholar
  60. 60.
    Bitter T. Combined disease-modifying chemotherapy for intractable rheumatoid arthritis. Clin Rheum Dis 1984; 10: 417–28PubMedGoogle Scholar
  61. 61.
    McKenna F, et al. 16th International Congress on Rheumatology, Sydney, Australia, 1985Google Scholar
  62. 62.
    Jaffe IA. Combination therapy of rheumatoid arthritis — rationale and overview. J Rheumatol Suppl. 1990; 25: 24–7PubMedGoogle Scholar
  63. 63.
    Lopez-Mendez A, Daniel WW, Reading JC, et al. Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis Rheum 1993; 36: 1364–9PubMedCrossRefGoogle Scholar
  64. 64.
    Taggart AJ, Hill J, Astbury C, et al. Sulphasalazine alone or in combination with D-penicillamine in rheumatoid arthritis. Br J Rheumatol 1987; 26: 32–6PubMedCrossRefGoogle Scholar
  65. 65.
    Lee S, Solomon G. Combination D-penicillamine and methotrexate therapy: proposal for early and aggressive treatment for rheumatoid arthritis. Bull Hosp Joint Dis Orthop Inst 1990; 50: 160–8Google Scholar
  66. 66.
    Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999; 93: 198–208PubMedCrossRefGoogle Scholar
  67. 67.
    Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000; 39: 655–65PubMedCrossRefGoogle Scholar
  68. 68.
    Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159: 2542–50PubMedCrossRefGoogle Scholar
  69. 69.
    Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353: 259–66PubMedCrossRefGoogle Scholar
  70. 70.
    Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000; 43: 495–505PubMedCrossRefGoogle Scholar
  71. 71.
    Emery P. Disease modification in rheumatoid arthritis with leflunomide. Scand J Rheumatol 1999;: 9–14Google Scholar
  72. 72.
    Kremer JM, Caldwell JR, Cannon GW, et al. The combinationSuppl. 112 of leflunomide (LEF) and methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who are failing on MTX treatment alone: a double-blind placebo (PLC) controlled study. Arthritis Rheum 2000; 43: 5943Google Scholar
  73. 73.
    Weinblatt ME, Dixon JA, Falchuk KR. Serious liver disease in a patient receiving methotrexate and leflunomide. Arthritis Rheum 2000; 43: 2609–11PubMedCrossRefGoogle Scholar
  74. 74.
    Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36: 1681–90PubMedCrossRefGoogle Scholar
  75. 75.
    Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125–7PubMedCrossRefGoogle Scholar
  76. 76.
    Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105–10PubMedCrossRefGoogle Scholar
  77. 77.
    Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552–63PubMedCrossRefGoogle Scholar
  78. 78.
    Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594–602PubMedCrossRefGoogle Scholar
  79. 79.
    Kavanaugh A, St. Clair EW, McCune WJ, et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000; 27: 841–50PubMedGoogle Scholar
  80. 80.
    Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9PubMedCrossRefGoogle Scholar
  81. 81.
    Moreland LW, Pratt PW, Mayes MD, et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995; 38: 1581–8PubMedCrossRefGoogle Scholar
  82. 82.
    Morgan A, Hale G, Waldmann H, et al. Prolonged combination therapy of RA using CD4 and TNFα blockade — a pilot study. Arthritis Rheum 1998; 41: S55Google Scholar
  83. 83.
    Morgan AW, Hale G, Rebello P, et al. Combination therapy with a TNF antagonist and a CD4 monoclonal antibody in rheumatoid arthritis. Arthritis Rheum 1997; 40: S81Google Scholar
  84. 84.
    Lipsky P, Clair WS, Furst D, et al. 54-week clinical and radiographic results from the ATTRACT trial: a phase III study of infliximab (Remicade(TM)) in patients with active RA despite methotrexate. Arthritis Rheum 1999; 42: S401Google Scholar
  85. 85.
    Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141–7PubMedCrossRefGoogle Scholar
  86. 86.
    Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93PubMedCrossRefGoogle Scholar
  87. 87.
    Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993; 20: 259–62PubMedGoogle Scholar
  88. 88.
    Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196–204PubMedCrossRefGoogle Scholar
  89. 89.
    Panayi GS, Choy EHS, Connolly DJA, et al. T cell hypothesis in rheumatoid arthritis tested by humanised non-depleting anti-CD4 monoclonal antibody treatment I: suppression of disease activity and acute phase response. Arthritis Rheum 1996; 39: S244Google Scholar
  90. 90.
    Levy R, Weisman M, Weisenhutter C, et al. Results of a placebo-controlled, multicenter trial using a primatised non-depleting, anti-CD4 monoclonal antibody in the treatment of rheumatoid arthritis. Arthritis Rheum 1996; 39: S122Google Scholar
  91. 91.
    Kavanaugh A, Davis LS, Nichols LA, et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994; 37: 992–9PubMedCrossRefGoogle Scholar
  92. 92.
    Kavanaugh A, Schulze-Koops H, Davis LS, et al. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum 1997; 40: 849–53PubMedCrossRefGoogle Scholar
  93. 93.
    Williams RO, Malfait AM, Butler DM, et al. Combination therapy with DMARDs and biological agents in collagen-induced arthritis. Clin Exp Rheumatol 1999; 17: S115–20PubMedGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Clinical and Academic Rheumatology, GKT School of MedicineKings College Hospital (Dulwich)LondonUK

Personalised recommendations